December 22, 2021 — IBA (Ion Beam Applications S.A.), a world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, announced it has signed a contract for the installation of a Proteus ONE proton therapy solution with the New Mexico Cancer Center in Albuquerque, NM, USA. The contract includes a long-term operation maintenance agreement.
The contract is for the delivery of a Proteus ONE solution, equipped with Pencil Beam Scanning (PBS), Cone Beam Computed Tomography (CBCT), Hand Pendant with contextual menus for easy patient positioning and the patient focused healthcare environment Philips Ambient Experience. New Mexico Cancer Center expects to treat its first patients by 2024.
The typical end-user price for a Proteus ONE system with a 10-year maintenance contract usually ranges between USD 40-50 million. IBA has received the first payment and will start recognizing revenue in 2021.
Olivier Legrain, Chief Executive Officer of IBA, commented: “This new contract with New Mexico Cancer Center will enable the delivery of IBA’s cutting-edge technology to the citizens of New Mexico for the first time. It is the 7th Proteus ONE system and 19th proton therapy system we have sold in the US, underlining our leading position in the US proton therapy market, and continuing to build upon the strong momentum in the region as we enter 2022. We look forward to collaborating with the team in Albuquerque and are pleased to welcome them to our Campus platform, the largest community of proton therapy experts.”
Barbara McAneny, Chief Executive Officer of New Mexico Cancer Center, said, “As one of the first free-standing cancer centers expanding into Proton therapy, New Mexico Cancer Center selected IBA’s Proteus ONE based on its strong technology and proven track record in hospital based systems. The delivery of the Proteus One will allow New Mexico Cancer Center to provide the people of New Mexico the ability to access the most advanced solution to fight cancer integrated into other modalities of care, at an affordable cost with the convenience of staying close to home.”
For more information: www.iba-worldwide.com
September 03, 2026 
